1-20 of 33
Jeremy A. Ross
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 1b Study of Step-up Dosing with ABBV-383, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma

Hira Mian, Muhamed Baljevic, Hila Magen, Moshe E Gatt, Irit Avivi Mazza, Emma Searle, Eben I Lichtman, John T. McKay, Torben Plesner, Cesar Rodriguez, Neha Korde, Hana Safah, Iuliana Vaxman, Chetasi Talati, Anders Erik Svensson, Ziyi Jin, Shane Lee, Thomas Doerr, Rajvineeth Kumar Pothacamury, Tanya S Rosenberg, Akshanth R Polepally, Jeremy A. Ross, Shaji Kumar
Journal: Blood
Blood (2024) 144 (Supplement 1): 1985.
https://doi.org/10.1182/blood-2024-206912
Published: 2024
Journal Articles

EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma

Clinical Trials & Observations
Ola Landgren, Thomas J. Prior, Tara Masterson, Christoph Heuck, Orlando F. Bueno, Ajeeta B. Dash, Hermann Einsele, Hartmut Goldschmidt, Stefan Knop, Cong Li, Ulf-Henrik Mellqvist, Ian McFadden, Corina Oprea, Jeremy A. Ross, Mihaela Talpes, Jay R. Hydren, Jennifer M. Ahlstrom, Dickran Kazandjian, Niels Weinhold, Rick Zhang, Maryalice Stetler-Stevenson, Gerald Marti, Sean M. Devlin
Journal: Blood
Blood (2024) 144 (4): 359–367.
https://doi.org/10.1182/blood.2024024371
Published: 2024
Includes: Supplemental data
Journal Articles

Bivalent BCMA Binding and Low Affinity CD3 T-Cell Engagement By Abbv-383 Drives Sustained Activation with Reduced T-Cell Exhaustion in Preclinical Models of Multiple Myeloma

David Sharon, Valerie Robinson, Claudie Hecquet, Kelly Calabrese, Cormac Cosgrove, Christine Mantis, Orlando Bueno, Aarif Ahsan, Adam Chervin, PK Epling-Burnette, Jeremy A Ross
Journal: Blood
Blood (2023) 142 (Supplement 1): 4666.
https://doi.org/10.1182/blood-2023-179039
Published: 2023
Journal Articles

Updated Safety and Efficacy Results of Abbv-383, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in a First-in-Human Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma

Ravi Vij, Shaji Kunnathu Kumar, Anita D'Souza, John T Mckay, Peter M. Voorhees, Alfred Chung, Sascha Alexander Tuchman, Neha Korde, Katja Weisel, Raphael Teipel, Orlando Bueno, Zhongling Feng, Tanya S Rosenberg, Rajvineeth Kumar Pothacamury, Akshanth R Polepally, Shane Lee, Ziyi Jin, Jeremy A Ross, Aarif Ahsan, Chetasi Talati, Cesar Rodriguez
Journal: Blood
Blood (2023) 142 (Supplement 1): 3378.
https://doi.org/10.1182/blood-2023-182388
Published: 2023
Journal Articles

Venetoclax in Combination with Daratumumab and Dexamethasone Elicits Deep, Durable Responses in Patients with t(11;14) Relapsed/Refractory Multiple Myeloma: Updated Analyses of Minimal Residual Disease Negativity in Phase 1/2 Study

Nizar J Bahlis, Hang Quach, Rachid Baz, Annette J. Vangsted, Shir-Jing Ho, Niels Abildgaard, Jacob Laubach, Vincent Ribrag, Peter M. Voorhees, Xifeng Wang, Orlando Bueno, Yan Luo, Jeremy A Ross, Jonathan L. Kaufman
Journal: Blood
Blood (2023) 142 (Supplement 1): 338.
https://doi.org/10.1182/blood-2023-180766
Published: 2023
Journal Articles

Pharmacokinetics and Immunogenicity of Abbv-383, a B-Cell Maturation Antigen (BCMA) × CD3 Bispecific T-Cell-Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Akshanth R Polepally, Carla Biesdorf, Muhammad Erfan Uddin, Nils Boehm, Jeremy A Ross, Shaji Kunnathu Kumar, Peter M. Voorhees, Anita D'Souza, Katja Weisel, Orlando Bueno, Chetasi Talati, Rajeev M Menon
Journal: Blood
Blood (2023) 142 (Supplement 1): 6722.
https://doi.org/10.1182/blood-2023-180127
Published: 2023
Journal Articles

Prevalence of t(11;14) Multiple Myeloma in Real-World Setting: Interim Analysis from the Medici Study

Andrew Spencer, Maria Gavriatopoulou, Daniel Coriu, Sandra Basic - Kinda, Roman Hajek, Ankit Pahwa, Rebekah Taylor, Kristin Lehn, Roby Joehanes, Jeremy A. Ross, Carlos Hader
Journal: Blood
Blood (2022) 140 (Supplement 1): 12481–12482.
https://doi.org/10.1182/blood-2022-159677
Published: 2022
Journal Articles

Dose Escalation and Expansion of Abbv-383 in Combination with Anti-Cancer Regimens in Relapsed or Refractory Multiple Myeloma

Cesar Rodriguez, Katja Weisel, Rachid C. Baz, Akshanth R. Polepally, Jeremy A. Ross, Ziyi Jin, Kristin D'Amico, Orlando F. Bueno, Leanne Lash Fleming, Peter M. Voorhees
Journal: Blood
Blood (2022) 140 (Supplement 1): 7326–7327.
https://doi.org/10.1182/blood-2022-157977
Published: 2022
Journal Articles

A Phase 1 First-in-Human Study of Abbv-383, a BCMA × CD3 Bispecific T-Cell-Redirecting Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma

Peter M. Voorhees, Anita D'Souza, Katja Weisel, David Duane Hurd, Raphael Teipel, Alfred Chung, Cesar Rodriguez, Sascha A. Tuchman, Neha Korde, Hana Safah, Orlando F. Bueno, Neil Pumford, Tanya S Rosenberg, Rajvineeth Kumar Pothacamury, Jeremy A. Ross, Akshanth R. Polepally, Shane Lee, Ziyi Jin, Chetasi Talati, Ravi Vij, Shaji K Kumar
Journal: Blood
Blood (2022) 140 (Supplement 1): 4401–4404.
https://doi.org/10.1182/blood-2022-167008
Published: 2022
Journal Articles

An Updated Safety and Efficacy Analysis of Venetoclax Plus Daratumumab and Dexamethasone in an Expansion Cohort of a Phase 1/2 Study of Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Jonathan L. Kaufman, Hang Quach, Rachid C. Baz, Annette Juul Vangsted, Shir-Jing Ho, Simon J Harrison, Torben Plesner, Philippe Moreau, Simon D. Gibbs, Eva Medvedova, Muhammad Jalaluddin, Jeremy A. Ross, Leanne Lash Fleming, Yan Luo, Nizar Jacques Bahlis
Journal: Blood
Blood (2022) 140 (Supplement 1): 7261–7263.
https://doi.org/10.1182/blood-2022-163809
Published: 2022
Journal Articles

Genomic Landscape of t(11;14) in Multiple Myeloma

Jeremy A. Ross, Herve Avet-Loiseau, Xiaotong Li, Raphaele Thiebaut-Millot, Carlos Hader
Journal: Blood
Blood (2022) 140 (Supplement 1): 10092–10093.
https://doi.org/10.1182/blood-2022-167167
Published: 2022
Journal Articles

A Sensitive Machine Learning-Based Approach to Assess Multiple Myeloma t(11;14) Genetic Subtype from Histopathology Images

Adam Stanford-Moore, Yi Liu, Chandan Akiti, Ali Behrooz, Bahar Rahsepar, Benjamin Glass, Aditee Shrotre, Jeremy A. Ross, Dorothy French
Journal: Blood
Blood (2022) 140 (Supplement 1): 7846–7847.
https://doi.org/10.1182/blood-2022-159522
Published: 2022
Journal Articles

Clinical Genomic Analyses Demonstrate t(11;14) Multiple Myeloma Retains B-Cell Biology and Distinct Mitochondrial Metabolism That Convey Increased Sensitivity to BCL-2 Inhibition By Venetoclax

David Sharon, Fengjiao Dunbar, Paul Jung, Xifeng Wang, Xiaotong Li, Christine Mantis, Orlando F. Bueno, Cyrille Touzeau, Philippe Moreau, Simon J Harrison, Luciano J. Costa, Jonathan L. Kaufman, Nizar J. Bahlis, Shaji K Kumar, Jeremy A. Ross, P.K. Epling-Burnette
Journal: Blood
Blood (2022) 140 (Supplement 1): 4242–4244.
https://doi.org/10.1182/blood-2022-160195
Published: 2022
Journal Articles

Real-World Effectiveness of Bortezomib Plus Dexamethasone in Patients with t(11;14) Positive Multiple Myeloma

Nnadozie Emechebe, Shaji Kumar, Hartmut Goldschmidt, Maria-Victoria Mateos, Juan Du, Kihyun Kim, Giampaolo Merlini, Meletios A. Dimopoulos, Heinz Ludwig, Hiroshi Handa, Carlos Fernandez de Larrea, Donna E. Reece, Wenming Chen, Noopur S. Raje, Sudeep Karve, Emma Arriola, Jeremy A. Ross, Brian G.M. Durie
Journal: Blood
Blood (2021) 138 (Supplement 1): 4725.
https://doi.org/10.1182/blood-2021-149270
Published: 2021
Journal Articles

Pomalidomide-Dexamethasone Effectiveness in t(11;14) Positive Relapsed Multiple Myeloma in Real-World Setting

Sudeep Karve, Shaji Kumar, Veronica Gonzalez De La Calle, Silvia Mangiacavalli, Chang-Ki Min, Efstathios Kastritis, Graca Esteves, Michel Delforge, Fernando Escalante, Jin Lu, Yang Liu, Max Bittrich, Charalampia Kyriakou, Andrew J. Yee, Emma Arriola, Jeremy A. Ross, Shivaji Manthena, Brian G.M. Durie
Journal: Blood
Blood (2021) 138 (Supplement 1): 3803.
https://doi.org/10.1182/blood-2021-149336
Published: 2021
Journal Articles

Final Overall Survival Results from BELLINI, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Shaji Kumar, Simon J Harrison, Michele Cavo, Javier de la Rubia, Rakesh Popat, Cristina J. Gasparetto, Vania Hungria, Hans Salwender, Kenshi Suzuki, Inho Kim, Maika Onishi, Grace Ku, Rajvineeth Kumar Pothacamury, Vasudha Sehgal, Abdullah A. Masud, Jeremy A. Ross, Edyta Dobkowska, Philippe Moreau
Journal: Blood
Blood (2021) 138 (Supplement 1): 84.
https://doi.org/10.1182/blood-2021-145757
Published: 2021
Journal Articles

Safety and Preliminary Efficacy from the Expansion Cohort of a Phase 1/2 Study of Venetoclax Plus Daratumumab and Dexamethasone Vs Daratumumab Plus Bortezomib and Dexamethasone in Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Jonathan L. Kaufman, Hang Quach, Rachid Baz, Annette J. Vangsted, Shir-Jing Ho, Simon J Harrison, Torben Plesner, Philippe Moreau, Simon D. Gibbs, Eva Medvedova, Vasudha Sehgal, Kingston Kang, Jeremy A. Ross, L. Leanne Lash-Fleming, Yan Luo, Nizar J. Bahlis
Journal: Blood
Blood (2021) 138 (Supplement 1): 817.
https://doi.org/10.1182/blood-2021-146043
Published: 2021
Journal Articles

Rapid and Sustained Reduction of Immunosuppressive T-Cells and Focusing of the T-Cell Repertoire in t(11;14) Relapsed/Refractory Multiple Myeloma Patients Treated with Venetoclax in Combination with Daratumumab and Dexamethasone

Nizar J. Bahlis, Jonathan L. Kaufman, Rachid Baz, Hang Quach, Shir-Jing Ho, Annette J. Vangsted, Torben Plesner, Philippe Moreau, Simon D. Gibbs, Eva Medvedova, Orlando F. Bueno, Yan Luo, Christine Mantis, Deeksha Vishwamitra, Jeremy A. Ross, Simon J Harrison
Journal: Blood
Blood (2021) 138 (Supplement 1): 1633.
https://doi.org/10.1182/blood-2021-146012
Published: 2021
Journal Articles

Assessment of Minimal Residual Disease By Next-Generation Sequencing and Fluorodeoxyglucose-Positron Emission Tomography in Patients with Relapsed/Refractory Multiple Myeloma Treated with Venetoclax in Combination with Carfilzomib and Dexamethasone

Luciano J. Costa, MD PhD, Nicholas Burwick, MD, Andrzej Jakubowiak, MD PhD, Jonathan L. Kaufman, MD, Fernando Cabanillas, MD, Monique Dail, PhD, Sudeep Karve, Abdullah A. Masud, PhD, Xiaoqing Yang, PhD, Orlando F. Bueno, Sarah Mudd, PhD, Jeremy A. Ross, Faith E. Davies
Journal: Blood
Blood (2020) 136 (Supplement 1): 4–5.
https://doi.org/10.1182/blood-2020-134737
Published: 2020
Journal Articles

Ex Vivo Drug Sensitivity and Functional Genomics Platform Identifies Novel Combinations Targeting Intrinsic and Extrinsic Apoptotic Signaling Pathways in Multiple Myeloma

Ariosto Siqueira Silva, PhD, Rafael Renatino-Canevarolo, PhD, Mark B. Meads, PhD, Maria D Coelho Siqueira Silva, MSc, Praneeth Reddy Sudalagunta, PhD, Christopher Cubitt, Gabriel De Avila, BS, Raghunandan Reddy Alugubelli, Amit Kulkarni, PhD, Melissa Mitchell, Hongyue Dai, Qi Zhang, PhD, Oliver Hampton, Xin Lu, Dimple A. Modi, PhD, Monica Motwani, PhD, Jason Harb, PhD, Jeremy A. Ross, Kenneth H. Shain, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 49–50.
https://doi.org/10.1182/blood-2020-134924
Published: 2020